nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—DDC—Dopamine metabolism—TYR—skin cancer	0.0393	0.176	CbGpPWpGaD
Amantadine—MAOB—Dopamine metabolism—TYR—skin cancer	0.0331	0.148	CbGpPWpGaD
Amantadine—GRIN2C—nerve—skin cancer	0.0225	0.145	CbGeAlD
Amantadine—GRIN2B—nerve—skin cancer	0.0178	0.115	CbGeAlD
Amantadine—GRIN2A—nerve—skin cancer	0.0155	0.1	CbGeAlD
Amantadine—DDC—nerve—skin cancer	0.0145	0.0938	CbGeAlD
Amantadine—DDC—Dopaminergic Neurogenesis—GLI2—skin cancer	0.00877	0.0392	CbGpPWpGaD
Amantadine—DDC—Dopaminergic Neurogenesis—GLI1—skin cancer	0.00825	0.0368	CbGpPWpGaD
Amantadine—MAOB—nerve—skin cancer	0.00747	0.0483	CbGeAlD
Amantadine—DRD2—nerve—skin cancer	0.0063	0.0407	CbGeAlD
Amantadine—DDC—Dopaminergic Neurogenesis—SHH—skin cancer	0.00596	0.0266	CbGpPWpGaD
Amantadine—ABCB1—Vismodegib—skin cancer	0.00548	0.557	CbGbCtD
Amantadine—GRIN2C—head—skin cancer	0.00533	0.0345	CbGeAlD
Amantadine—GRIN2D—head—skin cancer	0.00496	0.032	CbGeAlD
Amantadine—GRIN3A—head—skin cancer	0.00466	0.0301	CbGeAlD
Amantadine—SIGMAR1—nipple—skin cancer	0.00443	0.0286	CbGeAlD
Amantadine—GRIN1—head—skin cancer	0.00442	0.0286	CbGeAlD
Amantadine—MAOB—nipple—skin cancer	0.00424	0.0274	CbGeAlD
Amantadine—GRIN2B—head—skin cancer	0.00422	0.0272	CbGeAlD
Amantadine—DDC—female reproductive system—skin cancer	0.00412	0.0266	CbGeAlD
Amantadine—GRIN1—EPHB-mediated forward signaling—RASA1—skin cancer	0.00396	0.0177	CbGpPWpGaD
Amantadine—GRIN2B—EPHB-mediated forward signaling—RASA1—skin cancer	0.00387	0.0173	CbGpPWpGaD
Amantadine—GRIN2A—head—skin cancer	0.00368	0.0238	CbGeAlD
Amantadine—DDC—head—skin cancer	0.00344	0.0223	CbGeAlD
Amantadine—GRIN2C—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.00341	0.0152	CbGpPWpGaD
Amantadine—GRIN2D—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.00317	0.0141	CbGpPWpGaD
Amantadine—MAOB—connective tissue—skin cancer	0.00301	0.0194	CbGeAlD
Amantadine—ABCB1—Dactinomycin—skin cancer	0.00288	0.292	CbGbCtD
Amantadine—GRIN2C—Post NMDA receptor activation events—BRAF—skin cancer	0.0028	0.0125	CbGpPWpGaD
Amantadine—GRIN2D—Post NMDA receptor activation events—BRAF—skin cancer	0.00261	0.0116	CbGpPWpGaD
Amantadine—GRIN2A—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.0026	0.0116	CbGpPWpGaD
Amantadine—SIGMAR1—mammalian vulva—skin cancer	0.00259	0.0167	CbGeAlD
Amantadine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00258	0.0115	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—CSPG4—skin cancer	0.00252	0.0112	CbGpPWpGaD
Amantadine—MAOB—mammalian vulva—skin cancer	0.00248	0.016	CbGeAlD
Amantadine—DDC—lymph node—skin cancer	0.00241	0.0156	CbGeAlD
Amantadine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.0024	0.0107	CbGpPWpGaD
Amantadine—Alopecia—Imiquimod—skin cancer	0.0024	0.00392	CcSEcCtD
Amantadine—Mental disorder—Imiquimod—skin cancer	0.00238	0.00389	CcSEcCtD
Amantadine—Malnutrition—Imiquimod—skin cancer	0.00236	0.00386	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00234	0.00383	CcSEcCtD
Amantadine—Vomiting—Vismodegib—skin cancer	0.00233	0.00381	CcSEcCtD
Amantadine—Rash—Vismodegib—skin cancer	0.00231	0.00377	CcSEcCtD
Amantadine—Amnesia—Fluorouracil—skin cancer	0.00231	0.00377	CcSEcCtD
Amantadine—Dermatitis—Vismodegib—skin cancer	0.00231	0.00377	CcSEcCtD
Amantadine—GRIN1—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.00227	0.0101	CbGpPWpGaD
Amantadine—Anaphylactic shock—Vemurafenib—skin cancer	0.00226	0.0037	CcSEcCtD
Amantadine—DDC—Circadian rythm related genes—NKX2-1—skin cancer	0.00225	0.0101	CbGpPWpGaD
Amantadine—Dysphagia—Dactinomycin—skin cancer	0.00225	0.00367	CcSEcCtD
Amantadine—Cardiac failure—Fluorouracil—skin cancer	0.00222	0.00363	CcSEcCtD
Amantadine—Nervous system disorder—Vemurafenib—skin cancer	0.00222	0.00363	CcSEcCtD
Amantadine—GRIN2B—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.00221	0.00988	CbGpPWpGaD
Amantadine—Ataxia—Temozolomide—skin cancer	0.00221	0.00362	CcSEcCtD
Amantadine—Lethargy—Fluorouracil—skin cancer	0.00221	0.00361	CcSEcCtD
Amantadine—GRIN2C—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.0022	0.00981	CbGpPWpGaD
Amantadine—Skin disorder—Vemurafenib—skin cancer	0.0022	0.00359	CcSEcCtD
Amantadine—Nausea—Vismodegib—skin cancer	0.00217	0.00355	CcSEcCtD
Amantadine—Agitation—Imiquimod—skin cancer	0.00217	0.00355	CcSEcCtD
Amantadine—Osteoarthritis—Fluorouracil—skin cancer	0.00217	0.00354	CcSEcCtD
Amantadine—GRIN2A—Post NMDA receptor activation events—BRAF—skin cancer	0.00214	0.00956	CbGpPWpGaD
Amantadine—ABCB1—blood vessel—skin cancer	0.00214	0.0138	CbGeAlD
Amantadine—MAOB—female reproductive system—skin cancer	0.00212	0.0137	CbGeAlD
Amantadine—Hypotension—Vemurafenib—skin cancer	0.00211	0.00345	CcSEcCtD
Amantadine—Neutropenia—Dactinomycin—skin cancer	0.0021	0.00344	CcSEcCtD
Amantadine—Palpitations—Imiquimod—skin cancer	0.00209	0.00341	CcSEcCtD
Amantadine—Irritability—Fluorouracil—skin cancer	0.00207	0.00338	CcSEcCtD
Amantadine—Cardiac arrest—Fluorouracil—skin cancer	0.00206	0.00337	CcSEcCtD
Amantadine—Convulsion—Imiquimod—skin cancer	0.00205	0.00335	CcSEcCtD
Amantadine—GRIN2D—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00204	0.00912	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—RASA1—skin cancer	0.00204	0.00911	CbGpPWpGaD
Amantadine—Hypertension—Imiquimod—skin cancer	0.00204	0.00334	CcSEcCtD
Amantadine—Ataxia—Fluorouracil—skin cancer	0.00204	0.00333	CcSEcCtD
Amantadine—Dysphagia—Temozolomide—skin cancer	0.00203	0.00332	CcSEcCtD
Amantadine—Anxiety—Imiquimod—skin cancer	0.002	0.00328	CcSEcCtD
Amantadine—SLC22A1—head—skin cancer	0.002	0.0129	CbGeAlD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.002	0.00327	CcSEcCtD
Amantadine—GRIN2B—EPH-Ephrin signaling—RASA1—skin cancer	0.00199	0.00889	CbGpPWpGaD
Amantadine—Sweating increased—Temozolomide—skin cancer	0.00198	0.00324	CcSEcCtD
Amantadine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00197	0.00881	CbGpPWpGaD
Amantadine—Dry mouth—Imiquimod—skin cancer	0.00197	0.00322	CcSEcCtD
Amantadine—Decreased appetite—Vemurafenib—skin cancer	0.00197	0.00321	CcSEcCtD
Amantadine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00195	0.00319	CcSEcCtD
Amantadine—Fatigue—Vemurafenib—skin cancer	0.00195	0.00319	CcSEcCtD
Amantadine—Constipation—Vemurafenib—skin cancer	0.00193	0.00316	CcSEcCtD
Amantadine—Oedema—Imiquimod—skin cancer	0.00193	0.00315	CcSEcCtD
Amantadine—Lightheadedness—Docetaxel—skin cancer	0.00193	0.00315	CcSEcCtD
Amantadine—Pulmonary oedema—Docetaxel—skin cancer	0.00192	0.00314	CcSEcCtD
Amantadine—Neutropenia—Temozolomide—skin cancer	0.0019	0.00311	CcSEcCtD
Amantadine—Nervous system disorder—Imiquimod—skin cancer	0.00189	0.00309	CcSEcCtD
Amantadine—Tachycardia—Imiquimod—skin cancer	0.00188	0.00308	CcSEcCtD
Amantadine—Skin disorder—Imiquimod—skin cancer	0.00187	0.00306	CcSEcCtD
Amantadine—Dysphagia—Fluorouracil—skin cancer	0.00187	0.00306	CcSEcCtD
Amantadine—Agranulocytosis—Dactinomycin—skin cancer	0.00187	0.00306	CcSEcCtD
Amantadine—GRIN1—Post NMDA receptor activation events—BRAF—skin cancer	0.00187	0.00834	CbGpPWpGaD
Amantadine—Hyperhidrosis—Imiquimod—skin cancer	0.00186	0.00305	CcSEcCtD
Amantadine—Photosensitivity reaction—Temozolomide—skin cancer	0.00185	0.00303	CcSEcCtD
Amantadine—Anorexia—Imiquimod—skin cancer	0.00184	0.00301	CcSEcCtD
Amantadine—GRIN2B—Post NMDA receptor activation events—BRAF—skin cancer	0.00182	0.00813	CbGpPWpGaD
Amantadine—Body temperature increased—Vemurafenib—skin cancer	0.00179	0.00292	CcSEcCtD
Amantadine—MAOB—head—skin cancer	0.00177	0.0114	CbGeAlD
Amantadine—Insomnia—Imiquimod—skin cancer	0.00174	0.00285	CcSEcCtD
Amantadine—Paraesthesia—Imiquimod—skin cancer	0.00173	0.00283	CcSEcCtD
Amantadine—Cardiac failure congestive—Docetaxel—skin cancer	0.00172	0.00282	CcSEcCtD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00172	0.00768	CbGpPWpGaD
Amantadine—Dyspnoea—Imiquimod—skin cancer	0.00172	0.00281	CcSEcCtD
Amantadine—Somnolence—Imiquimod—skin cancer	0.00171	0.0028	CcSEcCtD
Amantadine—Photosensitivity reaction—Fluorouracil—skin cancer	0.00171	0.00279	CcSEcCtD
Amantadine—Alopecia—Bleomycin—skin cancer	0.0017	0.00279	CcSEcCtD
Amantadine—Dyspepsia—Imiquimod—skin cancer	0.0017	0.00278	CcSEcCtD
Amantadine—GRIN2A—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00168	0.00749	CbGpPWpGaD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00168	0.00749	CbGpPWpGaD
Amantadine—Decreased appetite—Imiquimod—skin cancer	0.00168	0.00274	CcSEcCtD
Amantadine—Hypersensitivity—Vemurafenib—skin cancer	0.00167	0.00272	CcSEcCtD
Amantadine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00166	0.00272	CcSEcCtD
Amantadine—Fatigue—Imiquimod—skin cancer	0.00166	0.00272	CcSEcCtD
Amantadine—Visual disturbance—Docetaxel—skin cancer	0.00165	0.0027	CcSEcCtD
Amantadine—Asthenia—Vemurafenib—skin cancer	0.00162	0.00265	CcSEcCtD
Amantadine—Hallucination—Temozolomide—skin cancer	0.00162	0.00265	CcSEcCtD
Amantadine—Urinary tract disorder—Temozolomide—skin cancer	0.00161	0.00263	CcSEcCtD
Amantadine—Oedema peripheral—Temozolomide—skin cancer	0.0016	0.00262	CcSEcCtD
Amantadine—Cardiac failure—Docetaxel—skin cancer	0.0016	0.00262	CcSEcCtD
Amantadine—Pruritus—Vemurafenib—skin cancer	0.0016	0.00262	CcSEcCtD
Amantadine—Lethargy—Docetaxel—skin cancer	0.0016	0.00261	CcSEcCtD
Amantadine—Urethral disorder—Temozolomide—skin cancer	0.00159	0.00261	CcSEcCtD
Amantadine—Alopecia—Dactinomycin—skin cancer	0.00159	0.0026	CcSEcCtD
Amantadine—Feeling abnormal—Imiquimod—skin cancer	0.00159	0.0026	CcSEcCtD
Amantadine—Visual impairment—Temozolomide—skin cancer	0.00157	0.00256	CcSEcCtD
Amantadine—GRIN2C—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.00157	0.007	CbGpPWpGaD
Amantadine—Agranulocytosis—Fluorouracil—skin cancer	0.00156	0.00255	CcSEcCtD
Amantadine—Diarrhoea—Vemurafenib—skin cancer	0.00155	0.00253	CcSEcCtD
Amantadine—Body temperature increased—Imiquimod—skin cancer	0.00152	0.00249	CcSEcCtD
Amantadine—Eye disorder—Temozolomide—skin cancer	0.00152	0.00249	CcSEcCtD
Amantadine—Cardiac disorder—Temozolomide—skin cancer	0.00151	0.00247	CcSEcCtD
Amantadine—Leukopenia—Bleomycin—skin cancer	0.0015	0.00246	CcSEcCtD
Amantadine—Dizziness—Vemurafenib—skin cancer	0.0015	0.00245	CcSEcCtD
Amantadine—DRD2—head—skin cancer	0.00149	0.00966	CbGeAlD
Amantadine—ABCB1—Docetaxel—skin cancer	0.00149	0.151	CbGbCtD
Amantadine—Angiopathy—Temozolomide—skin cancer	0.00148	0.00241	CcSEcCtD
Amantadine—Ataxia—Docetaxel—skin cancer	0.00147	0.0024	CcSEcCtD
Amantadine—Mediastinal disorder—Temozolomide—skin cancer	0.00147	0.0024	CcSEcCtD
Amantadine—GRIN1—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00146	0.00653	CbGpPWpGaD
Amantadine—GRIN2D—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.00146	0.0065	CbGpPWpGaD
Amantadine—Liver function test abnormal—Docetaxel—skin cancer	0.00144	0.00236	CcSEcCtD
Amantadine—Vomiting—Vemurafenib—skin cancer	0.00144	0.00235	CcSEcCtD
Amantadine—Alopecia—Temozolomide—skin cancer	0.00144	0.00235	CcSEcCtD
Amantadine—Orthostatic hypotension—Docetaxel—skin cancer	0.00143	0.00234	CcSEcCtD
Amantadine—GRIN2B—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00143	0.00637	CbGpPWpGaD
Amantadine—Rash—Vemurafenib—skin cancer	0.00143	0.00233	CcSEcCtD
Amantadine—Mental disorder—Temozolomide—skin cancer	0.00142	0.00233	CcSEcCtD
Amantadine—Dermatitis—Vemurafenib—skin cancer	0.00142	0.00233	CcSEcCtD
Amantadine—Hypersensitivity—Imiquimod—skin cancer	0.00142	0.00232	CcSEcCtD
Amantadine—Headache—Vemurafenib—skin cancer	0.00142	0.00232	CcSEcCtD
Amantadine—Malnutrition—Temozolomide—skin cancer	0.00142	0.00232	CcSEcCtD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.00141	0.00631	CbGpPWpGaD
Amantadine—Leukopenia—Dactinomycin—skin cancer	0.0014	0.00229	CcSEcCtD
Amantadine—Asthenia—Imiquimod—skin cancer	0.00138	0.00226	CcSEcCtD
Amantadine—Confusional state—Bleomycin—skin cancer	0.00138	0.00226	CcSEcCtD
Amantadine—Oedema—Bleomycin—skin cancer	0.00137	0.00224	CcSEcCtD
Amantadine—Anaphylactic shock—Bleomycin—skin cancer	0.00137	0.00224	CcSEcCtD
Amantadine—Pruritus—Imiquimod—skin cancer	0.00136	0.00223	CcSEcCtD
Amantadine—Dysphagia—Docetaxel—skin cancer	0.00135	0.00221	CcSEcCtD
Amantadine—Nausea—Vemurafenib—skin cancer	0.00134	0.0022	CcSEcCtD
Amantadine—Arrhythmia—Fluorouracil—skin cancer	0.00134	0.00219	CcSEcCtD
Amantadine—Vision blurred—Temozolomide—skin cancer	0.00133	0.00218	CcSEcCtD
Amantadine—Tremor—Temozolomide—skin cancer	0.00133	0.00217	CcSEcCtD
Amantadine—Alopecia—Fluorouracil—skin cancer	0.00132	0.00217	CcSEcCtD
Amantadine—GRIN1—Axon guidance—SCN10A—skin cancer	0.00132	0.0059	CbGpPWpGaD
Amantadine—Diarrhoea—Imiquimod—skin cancer	0.00132	0.00216	CcSEcCtD
Amantadine—Anorexia—Bleomycin—skin cancer	0.00131	0.00214	CcSEcCtD
Amantadine—Agitation—Temozolomide—skin cancer	0.0013	0.00213	CcSEcCtD
Amantadine—SIGMAR1—lymph node—skin cancer	0.0013	0.00837	CbGeAlD
Amantadine—GRIN2C—Post NMDA receptor activation events—HRAS—skin cancer	0.00129	0.00576	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—SCN10A—skin cancer	0.00129	0.00575	CbGpPWpGaD
Amantadine—Hypotension—Bleomycin—skin cancer	0.00128	0.00209	CcSEcCtD
Amantadine—Oedema—Dactinomycin—skin cancer	0.00128	0.00209	CcSEcCtD
Amantadine—Dizziness—Imiquimod—skin cancer	0.00128	0.00209	CcSEcCtD
Amantadine—Leukopenia—Temozolomide—skin cancer	0.00127	0.00207	CcSEcCtD
Amantadine—Neutropenia—Docetaxel—skin cancer	0.00126	0.00207	CcSEcCtD
Amantadine—Palpitations—Temozolomide—skin cancer	0.00125	0.00205	CcSEcCtD
Amantadine—MAOB—lymph node—skin cancer	0.00124	0.00802	CbGeAlD
Amantadine—Paraesthesia—Bleomycin—skin cancer	0.00123	0.00201	CcSEcCtD
Amantadine—Vision blurred—Fluorouracil—skin cancer	0.00123	0.00201	CcSEcCtD
Amantadine—Convulsion—Temozolomide—skin cancer	0.00123	0.00201	CcSEcCtD
Amantadine—Vomiting—Imiquimod—skin cancer	0.00123	0.002	CcSEcCtD
Amantadine—Hypertension—Temozolomide—skin cancer	0.00122	0.002	CcSEcCtD
Amantadine—Dyspnoea—Bleomycin—skin cancer	0.00122	0.002	CcSEcCtD
Amantadine—Anorexia—Dactinomycin—skin cancer	0.00122	0.00199	CcSEcCtD
Amantadine—Rash—Imiquimod—skin cancer	0.00122	0.00199	CcSEcCtD
Amantadine—Dermatitis—Imiquimod—skin cancer	0.00121	0.00199	CcSEcCtD
Amantadine—Headache—Imiquimod—skin cancer	0.00121	0.00198	CcSEcCtD
Amantadine—Anxiety—Temozolomide—skin cancer	0.0012	0.00196	CcSEcCtD
Amantadine—GRIN2D—Post NMDA receptor activation events—HRAS—skin cancer	0.0012	0.00535	CbGpPWpGaD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.0012	0.00196	CcSEcCtD
Amantadine—GRIN2A—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.0012	0.00534	CbGpPWpGaD
Amantadine—Decreased appetite—Bleomycin—skin cancer	0.00119	0.00195	CcSEcCtD
Amantadine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.00119	0.0053	CbGpPWpGaD
Amantadine—Dry mouth—Temozolomide—skin cancer	0.00118	0.00193	CcSEcCtD
Amantadine—Leukopenia—Fluorouracil—skin cancer	0.00117	0.00191	CcSEcCtD
Amantadine—Confusional state—Temozolomide—skin cancer	0.00117	0.00191	CcSEcCtD
Amantadine—Anaphylactic shock—Temozolomide—skin cancer	0.00116	0.00189	CcSEcCtD
Amantadine—Oedema—Temozolomide—skin cancer	0.00116	0.00189	CcSEcCtD
Amantadine—Nausea—Imiquimod—skin cancer	0.00115	0.00187	CcSEcCtD
Amantadine—Nervous system disorder—Temozolomide—skin cancer	0.00113	0.00185	CcSEcCtD
Amantadine—Convulsion—Fluorouracil—skin cancer	0.00113	0.00185	CcSEcCtD
Amantadine—Feeling abnormal—Bleomycin—skin cancer	0.00113	0.00185	CcSEcCtD
Amantadine—Agranulocytosis—Docetaxel—skin cancer	0.00112	0.00184	CcSEcCtD
Amantadine—Skin disorder—Temozolomide—skin cancer	0.00112	0.00184	CcSEcCtD
Amantadine—Hyperhidrosis—Temozolomide—skin cancer	0.00112	0.00183	CcSEcCtD
Amantadine—Decreased appetite—Dactinomycin—skin cancer	0.00111	0.00182	CcSEcCtD
Amantadine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.0011	0.00493	CbGpPWpGaD
Amantadine—Fatigue—Dactinomycin—skin cancer	0.0011	0.0018	CcSEcCtD
Amantadine—Anorexia—Temozolomide—skin cancer	0.0011	0.0018	CcSEcCtD
Amantadine—Body temperature increased—Bleomycin—skin cancer	0.00108	0.00177	CcSEcCtD
Amantadine—Confusional state—Fluorouracil—skin cancer	0.00107	0.00176	CcSEcCtD
Amantadine—Urinary tract disorder—Docetaxel—skin cancer	0.00107	0.00175	CcSEcCtD
Amantadine—Oedema peripheral—Docetaxel—skin cancer	0.00107	0.00174	CcSEcCtD
Amantadine—Oedema—Fluorouracil—skin cancer	0.00106	0.00174	CcSEcCtD
Amantadine—Anaphylactic shock—Fluorouracil—skin cancer	0.00106	0.00174	CcSEcCtD
Amantadine—Urethral disorder—Docetaxel—skin cancer	0.00106	0.00173	CcSEcCtD
Amantadine—Feeling abnormal—Dactinomycin—skin cancer	0.00105	0.00172	CcSEcCtD
Amantadine—Insomnia—Temozolomide—skin cancer	0.00105	0.00171	CcSEcCtD
Amantadine—Nervous system disorder—Fluorouracil—skin cancer	0.00104	0.00171	CcSEcCtD
Amantadine—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.00104	0.00466	CbGpPWpGaD
Amantadine—Visual impairment—Docetaxel—skin cancer	0.00104	0.0017	CcSEcCtD
Amantadine—ABCB1—epithelium—skin cancer	0.00104	0.00673	CbGeAlD
Amantadine—Tachycardia—Fluorouracil—skin cancer	0.00104	0.0017	CcSEcCtD
Amantadine—Paraesthesia—Temozolomide—skin cancer	0.00104	0.0017	CcSEcCtD
Amantadine—Dyspnoea—Temozolomide—skin cancer	0.00103	0.00168	CcSEcCtD
Amantadine—Somnolence—Temozolomide—skin cancer	0.00103	0.00168	CcSEcCtD
Amantadine—GRIN2B—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.00102	0.00454	CbGpPWpGaD
Amantadine—Dyspepsia—Temozolomide—skin cancer	0.00102	0.00166	CcSEcCtD
Amantadine—Anorexia—Fluorouracil—skin cancer	0.00101	0.00166	CcSEcCtD
Amantadine—Eye disorder—Docetaxel—skin cancer	0.00101	0.00165	CcSEcCtD
Amantadine—Body temperature increased—Dactinomycin—skin cancer	0.00101	0.00165	CcSEcCtD
Amantadine—Hypersensitivity—Bleomycin—skin cancer	0.00101	0.00165	CcSEcCtD
Amantadine—Decreased appetite—Temozolomide—skin cancer	0.001	0.00164	CcSEcCtD
Amantadine—Cardiac disorder—Docetaxel—skin cancer	0.001	0.00164	CcSEcCtD
Amantadine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000998	0.00163	CcSEcCtD
Amantadine—Fatigue—Temozolomide—skin cancer	0.000996	0.00163	CcSEcCtD
Amantadine—Hypotension—Fluorouracil—skin cancer	0.000995	0.00163	CcSEcCtD
Amantadine—Constipation—Temozolomide—skin cancer	0.000988	0.00162	CcSEcCtD
Amantadine—GRIN2A—Post NMDA receptor activation events—HRAS—skin cancer	0.000985	0.0044	CbGpPWpGaD
Amantadine—Asthenia—Bleomycin—skin cancer	0.000983	0.00161	CcSEcCtD
Amantadine—Angiopathy—Docetaxel—skin cancer	0.000981	0.0016	CcSEcCtD
Amantadine—Mediastinal disorder—Docetaxel—skin cancer	0.000975	0.00159	CcSEcCtD
Amantadine—Pruritus—Bleomycin—skin cancer	0.000969	0.00158	CcSEcCtD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000967	0.00432	CbGpPWpGaD
Amantadine—Arrhythmia—Docetaxel—skin cancer	0.000966	0.00158	CcSEcCtD
Amantadine—Insomnia—Fluorouracil—skin cancer	0.000963	0.00157	CcSEcCtD
Amantadine—Paraesthesia—Fluorouracil—skin cancer	0.000956	0.00156	CcSEcCtD
Amantadine—Alopecia—Docetaxel—skin cancer	0.000956	0.00156	CcSEcCtD
Amantadine—Feeling abnormal—Temozolomide—skin cancer	0.000952	0.00156	CcSEcCtD
Amantadine—Dyspnoea—Fluorouracil—skin cancer	0.000949	0.00155	CcSEcCtD
Amantadine—Mental disorder—Docetaxel—skin cancer	0.000948	0.00155	CcSEcCtD
Amantadine—Somnolence—Fluorouracil—skin cancer	0.000946	0.00155	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—SCN10A—skin cancer	0.000943	0.00421	CbGpPWpGaD
Amantadine—Malnutrition—Docetaxel—skin cancer	0.000942	0.00154	CcSEcCtD
Amantadine—Hypersensitivity—Dactinomycin—skin cancer	0.000941	0.00154	CcSEcCtD
Amantadine—Dyspepsia—Fluorouracil—skin cancer	0.000937	0.00153	CcSEcCtD
Amantadine—Decreased appetite—Fluorouracil—skin cancer	0.000925	0.00151	CcSEcCtD
Amantadine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000919	0.0015	CcSEcCtD
Amantadine—GRIN2B—Developmental Biology—SCN10A—skin cancer	0.000919	0.0041	CbGpPWpGaD
Amantadine—Asthenia—Dactinomycin—skin cancer	0.000917	0.0015	CcSEcCtD
Amantadine—Body temperature increased—Temozolomide—skin cancer	0.000913	0.00149	CcSEcCtD
Amantadine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000907	0.00405	CbGpPWpGaD
Amantadine—ABCB1—mammalian vulva—skin cancer	0.000903	0.00584	CbGeAlD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000899	0.00401	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—NKX2-1—skin cancer	0.000888	0.00396	CbGpPWpGaD
Amantadine—Feeling abnormal—Fluorouracil—skin cancer	0.000877	0.00143	CcSEcCtD
Amantadine—Diarrhoea—Dactinomycin—skin cancer	0.000874	0.00143	CcSEcCtD
Amantadine—Vomiting—Bleomycin—skin cancer	0.000871	0.00142	CcSEcCtD
Amantadine—Rash—Bleomycin—skin cancer	0.000864	0.00141	CcSEcCtD
Amantadine—Dermatitis—Bleomycin—skin cancer	0.000863	0.00141	CcSEcCtD
Amantadine—GRIN1—Post NMDA receptor activation events—HRAS—skin cancer	0.000859	0.00383	CbGpPWpGaD
Amantadine—Hypersensitivity—Temozolomide—skin cancer	0.000851	0.00139	CcSEcCtD
Amantadine—Leukopenia—Docetaxel—skin cancer	0.000843	0.00138	CcSEcCtD
Amantadine—Body temperature increased—Fluorouracil—skin cancer	0.000842	0.00138	CcSEcCtD
Amantadine—GRIN2B—Post NMDA receptor activation events—HRAS—skin cancer	0.000837	0.00374	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—CDK4—skin cancer	0.000835	0.00373	CbGpPWpGaD
Amantadine—Palpitations—Docetaxel—skin cancer	0.000832	0.00136	CcSEcCtD
Amantadine—Asthenia—Temozolomide—skin cancer	0.000829	0.00136	CcSEcCtD
Amantadine—SLC22A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000819	0.00366	CbGpPWpGaD
Amantadine—Pruritus—Temozolomide—skin cancer	0.000817	0.00134	CcSEcCtD
Amantadine—Convulsion—Docetaxel—skin cancer	0.000816	0.00133	CcSEcCtD
Amantadine—Nausea—Bleomycin—skin cancer	0.000814	0.00133	CcSEcCtD
Amantadine—Hypertension—Docetaxel—skin cancer	0.000813	0.00133	CcSEcCtD
Amantadine—Vomiting—Dactinomycin—skin cancer	0.000812	0.00133	CcSEcCtD
Amantadine—Rash—Dactinomycin—skin cancer	0.000805	0.00132	CcSEcCtD
Amantadine—ABCB1—lymphoid tissue—skin cancer	0.000802	0.00518	CbGeAlD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000796	0.0013	CcSEcCtD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000791	0.00353	CbGpPWpGaD
Amantadine—GRIN1—EPHB-mediated forward signaling—HRAS—skin cancer	0.000791	0.00353	CbGpPWpGaD
Amantadine—Diarrhoea—Temozolomide—skin cancer	0.000791	0.00129	CcSEcCtD
Amantadine—Hypersensitivity—Fluorouracil—skin cancer	0.000784	0.00128	CcSEcCtD
Amantadine—Dry mouth—Docetaxel—skin cancer	0.000784	0.00128	CcSEcCtD
Amantadine—Confusional state—Docetaxel—skin cancer	0.000775	0.00127	CcSEcCtD
Amantadine—ABCB1—female reproductive system—skin cancer	0.000773	0.005	CbGeAlD
Amantadine—GRIN2B—EPHB-mediated forward signaling—HRAS—skin cancer	0.000771	0.00344	CbGpPWpGaD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000771	0.00344	CbGpPWpGaD
Amantadine—Anaphylactic shock—Docetaxel—skin cancer	0.000768	0.00126	CcSEcCtD
Amantadine—Oedema—Docetaxel—skin cancer	0.000768	0.00126	CcSEcCtD
Amantadine—Dizziness—Temozolomide—skin cancer	0.000764	0.00125	CcSEcCtD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000763	0.00341	CbGpPWpGaD
Amantadine—Nausea—Dactinomycin—skin cancer	0.000759	0.00124	CcSEcCtD
Amantadine—GRIN1—Axon guidance—RASA1—skin cancer	0.000759	0.00339	CbGpPWpGaD
Amantadine—Nervous system disorder—Docetaxel—skin cancer	0.000754	0.00123	CcSEcCtD
Amantadine—Pruritus—Fluorouracil—skin cancer	0.000753	0.00123	CcSEcCtD
Amantadine—Tachycardia—Docetaxel—skin cancer	0.00075	0.00123	CcSEcCtD
Amantadine—Skin disorder—Docetaxel—skin cancer	0.000746	0.00122	CcSEcCtD
Amantadine—GRIN2B—Axon guidance—RASA1—skin cancer	0.00074	0.0033	CbGpPWpGaD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000738	0.0033	CbGpPWpGaD
Amantadine—GRIN2C—Alzheimers Disease—TP53—skin cancer	0.000735	0.00328	CbGpPWpGaD
Amantadine—Vomiting—Temozolomide—skin cancer	0.000735	0.0012	CcSEcCtD
Amantadine—Anorexia—Docetaxel—skin cancer	0.000732	0.0012	CcSEcCtD
Amantadine—Rash—Temozolomide—skin cancer	0.000729	0.00119	CcSEcCtD
Amantadine—Diarrhoea—Fluorouracil—skin cancer	0.000728	0.00119	CcSEcCtD
Amantadine—Dermatitis—Temozolomide—skin cancer	0.000728	0.00119	CcSEcCtD
Amantadine—GRIN2C—Transmission across Chemical Synapses—BRAF—skin cancer	0.000727	0.00325	CbGpPWpGaD
Amantadine—Headache—Temozolomide—skin cancer	0.000724	0.00118	CcSEcCtD
Amantadine—Hypotension—Docetaxel—skin cancer	0.000718	0.00117	CcSEcCtD
Amantadine—Dizziness—Fluorouracil—skin cancer	0.000704	0.00115	CcSEcCtD
Amantadine—Insomnia—Docetaxel—skin cancer	0.000695	0.00114	CcSEcCtD
Amantadine—Paraesthesia—Docetaxel—skin cancer	0.00069	0.00113	CcSEcCtD
Amantadine—Nausea—Temozolomide—skin cancer	0.000686	0.00112	CcSEcCtD
Amantadine—Dyspnoea—Docetaxel—skin cancer	0.000685	0.00112	CcSEcCtD
Amantadine—GRIN2D—Alzheimers Disease—TP53—skin cancer	0.000683	0.00305	CbGpPWpGaD
Amantadine—Somnolence—Docetaxel—skin cancer	0.000683	0.00112	CcSEcCtD
Amantadine—Vomiting—Fluorouracil—skin cancer	0.000677	0.00111	CcSEcCtD
Amantadine—Dyspepsia—Docetaxel—skin cancer	0.000676	0.00111	CcSEcCtD
Amantadine—GRIN2D—Transmission across Chemical Synapses—BRAF—skin cancer	0.000676	0.00302	CbGpPWpGaD
Amantadine—Rash—Fluorouracil—skin cancer	0.000671	0.0011	CcSEcCtD
Amantadine—Dermatitis—Fluorouracil—skin cancer	0.000671	0.0011	CcSEcCtD
Amantadine—Decreased appetite—Docetaxel—skin cancer	0.000668	0.00109	CcSEcCtD
Amantadine—Headache—Fluorouracil—skin cancer	0.000667	0.00109	CcSEcCtD
Amantadine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000663	0.00108	CcSEcCtD
Amantadine—Fatigue—Docetaxel—skin cancer	0.000662	0.00108	CcSEcCtD
Amantadine—Constipation—Docetaxel—skin cancer	0.000657	0.00107	CcSEcCtD
Amantadine—ABCB1—head—skin cancer	0.000646	0.00418	CbGeAlD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000644	0.00288	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—CDK4—skin cancer	0.000634	0.00283	CbGpPWpGaD
Amantadine—Feeling abnormal—Docetaxel—skin cancer	0.000633	0.00104	CcSEcCtD
Amantadine—Nausea—Fluorouracil—skin cancer	0.000632	0.00103	CcSEcCtD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000628	0.0028	CbGpPWpGaD
Amantadine—Body temperature increased—Docetaxel—skin cancer	0.000607	0.000993	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—PTGS2—skin cancer	0.000597	0.00266	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00059	0.00263	CbGpPWpGaD
Amantadine—Hypersensitivity—Docetaxel—skin cancer	0.000566	0.000926	CcSEcCtD
Amantadine—GRIN2A—Alzheimers Disease—TP53—skin cancer	0.000561	0.00251	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—BRAF—skin cancer	0.000557	0.00249	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—BRAF—skin cancer	0.000555	0.00248	CbGpPWpGaD
Amantadine—Asthenia—Docetaxel—skin cancer	0.000551	0.000902	CcSEcCtD
Amantadine—Pruritus—Docetaxel—skin cancer	0.000544	0.000889	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—RASA1—skin cancer	0.000541	0.00242	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—PTCH2—skin cancer	0.000532	0.00238	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—RASA1—skin cancer	0.000528	0.00236	CbGpPWpGaD
Amantadine—Diarrhoea—Docetaxel—skin cancer	0.000526	0.00086	CcSEcCtD
Amantadine—GRIN2D—Neuronal System—BRAF—skin cancer	0.000518	0.00231	CbGpPWpGaD
Amantadine—Dizziness—Docetaxel—skin cancer	0.000508	0.000831	CcSEcCtD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000505	0.00226	CbGpPWpGaD
Amantadine—GRIN1—Alzheimers Disease—TP53—skin cancer	0.000489	0.00219	CbGpPWpGaD
Amantadine—Vomiting—Docetaxel—skin cancer	0.000489	0.000799	CcSEcCtD
Amantadine—Rash—Docetaxel—skin cancer	0.000484	0.000792	CcSEcCtD
Amantadine—GRIN1—Transmission across Chemical Synapses—BRAF—skin cancer	0.000484	0.00216	CbGpPWpGaD
Amantadine—Dermatitis—Docetaxel—skin cancer	0.000484	0.000792	CcSEcCtD
Amantadine—Headache—Docetaxel—skin cancer	0.000481	0.000787	CcSEcCtD
Amantadine—GRIN2B—Alzheimers Disease—TP53—skin cancer	0.000477	0.00213	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—BRAF—skin cancer	0.000472	0.00211	CbGpPWpGaD
Amantadine—DDC—Metabolism—PLIN2—skin cancer	0.00046	0.00205	CbGpPWpGaD
Amantadine—Nausea—Docetaxel—skin cancer	0.000456	0.000746	CcSEcCtD
Amantadine—ABCB1—lymph node—skin cancer	0.000452	0.00292	CbGeAlD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000445	0.00199	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—BRAF—skin cancer	0.000425	0.0019	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	0.000422	0.00188	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000416	0.00186	CbGpPWpGaD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000413	0.00185	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—HRAS—skin cancer	0.000407	0.00182	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—HRAS—skin cancer	0.000397	0.00177	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000388	0.00173	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000388	0.00173	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PLIN2—skin cancer	0.000387	0.00173	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—MC1R—skin cancer	0.000385	0.00172	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—BRAF—skin cancer	0.000371	0.00166	CbGpPWpGaD
Amantadine—DDC—Metabolism—CSPG4—skin cancer	0.000371	0.00166	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—BRAF—skin cancer	0.000362	0.00161	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TP53—skin cancer	0.000355	0.00159	CbGpPWpGaD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.00034	0.00152	CbGpPWpGaD
Amantadine—GRIN2C—Transmission across Chemical Synapses—HRAS—skin cancer	0.000334	0.00149	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000332	0.00148	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000331	0.00148	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RHOU—skin cancer	0.00033	0.00148	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—IL6—skin cancer	0.000325	0.00145	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000314	0.0014	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CSPG4—skin cancer	0.000312	0.00139	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—HRAS—skin cancer	0.000311	0.00139	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—IL6—skin cancer	0.000303	0.00135	CbGpPWpGaD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000296	0.00132	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—HRAS—skin cancer	0.00029	0.00129	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000289	0.00129	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—HRAS—skin cancer	0.000282	0.00126	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—SHH—skin cancer	0.000274	0.00122	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PTCH2—skin cancer	0.000273	0.00122	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TP53—skin cancer	0.00027	0.0012	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CDK4—skin cancer	0.000265	0.00119	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—IL6—skin cancer	0.00026	0.00116	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—SMO—skin cancer	0.00026	0.00116	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—PTCH1—skin cancer	0.00026	0.00116	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CDK4—skin cancer	0.000259	0.00116	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—HRAS—skin cancer	0.000256	0.00114	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—HRAS—skin cancer	0.000255	0.00114	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—PTGER4—skin cancer	0.000253	0.00113	CbGpPWpGaD
Amantadine—DDC—Metabolism—ENO2—skin cancer	0.000252	0.00113	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—BRAF—skin cancer	0.000252	0.00112	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—CDK4—skin cancer	0.00025	0.00112	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—IL6—skin cancer	0.000247	0.0011	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—HRAS—skin cancer	0.000238	0.00106	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—BRAF—skin cancer	0.000235	0.00105	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000227	0.00101	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—HRAS—skin cancer	0.000223	0.000994	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—MC1R—skin cancer	0.000217	0.000971	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—HRAS—skin cancer	0.000217	0.000969	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ENO2—skin cancer	0.000212	0.000948	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—NRAS—skin cancer	0.000207	0.000924	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PLIN2—skin cancer	0.000206	0.000918	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—NRAS—skin cancer	0.000202	0.0009	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MC1R—skin cancer	0.000197	0.000882	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—HRAS—skin cancer	0.000196	0.000873	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—BRAF—skin cancer	0.000193	0.000861	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PLIN2—skin cancer	0.000192	0.000855	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—BRAF—skin cancer	0.00018	0.000803	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—KRAS—skin cancer	0.000178	0.000795	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—KRAS—skin cancer	0.000174	0.000775	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—HRAS—skin cancer	0.000171	0.000762	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—HRAS—skin cancer	0.000166	0.000742	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CSPG4—skin cancer	0.000166	0.00074	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTCH2—skin cancer	0.000161	0.00072	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000161	0.00072	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CSPG4—skin cancer	0.000154	0.00069	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—HRAS—skin cancer	0.000151	0.000676	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—NRAS—skin cancer	0.000148	0.000659	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—HRAS—skin cancer	0.000148	0.000659	CbGpPWpGaD
Amantadine—DDC—Metabolism—ERCC2—skin cancer	0.000146	0.000654	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—IL6—skin cancer	0.000145	0.000647	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—NRAS—skin cancer	0.000144	0.000643	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PTGER4—skin cancer	0.000143	0.000638	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—IL6—skin cancer	0.000141	0.00063	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—SHH—skin cancer	0.000141	0.000628	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PTCH1—skin cancer	0.000133	0.000596	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—SMO—skin cancer	0.000133	0.000596	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PTGER4—skin cancer	0.00013	0.00058	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—KRAS—skin cancer	0.000127	0.000567	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—KRAS—skin cancer	0.000124	0.000553	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ERCC2—skin cancer	0.000123	0.00055	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GLI2—skin cancer	0.000122	0.000546	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MC1R—skin cancer	0.000117	0.000521	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—HRAS—skin cancer	0.000116	0.000517	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000115	0.000515	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GLI1—skin cancer	0.000115	0.000513	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ENO2—skin cancer	0.000113	0.000503	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PLIN2—skin cancer	0.000112	0.000501	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SUFU—skin cancer	0.000109	0.000487	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HRAS—skin cancer	0.000108	0.000482	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—HRAS—skin cancer	0.000108	0.000482	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—skin cancer	0.000106	0.000475	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—HRAS—skin cancer	0.000105	0.00047	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ENO2—skin cancer	0.000105	0.000469	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—IL6—skin cancer	0.000103	0.000461	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—IL6—skin cancer	0.000101	0.00045	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—IL6—skin cancer	9.74e-05	0.000435	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CSPG4—skin cancer	9.05e-05	0.000404	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—HRAS—skin cancer	8.87e-05	0.000396	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS2—skin cancer	8.78e-05	0.000392	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SHH—skin cancer	8.31e-05	0.000371	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—HRAS—skin cancer	8.27e-05	0.000369	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RASA1—skin cancer	8.26e-05	0.000369	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SMO—skin cancer	7.88e-05	0.000352	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTCH1—skin cancer	7.88e-05	0.000352	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	7.72e-05	0.000345	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTGER4—skin cancer	7.67e-05	0.000342	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS2—skin cancer	7.39e-05	0.00033	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	6.86e-05	0.000306	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FOXO4—skin cancer	6.78e-05	0.000303	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ERCC2—skin cancer	6.54e-05	0.000292	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ENO2—skin cancer	6.15e-05	0.000275	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ERCC2—skin cancer	6.1e-05	0.000272	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TERT—skin cancer	4.53e-05	0.000202	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS2—skin cancer	3.92e-05	0.000175	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—NRAS—skin cancer	3.81e-05	0.00017	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS2—skin cancer	3.66e-05	0.000163	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BRAF—skin cancer	3.58e-05	0.00016	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ERCC2—skin cancer	3.57e-05	0.00016	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KRAS—skin cancer	3.28e-05	0.000147	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—HRAS—skin cancer	2.79e-05	0.000125	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL6—skin cancer	2.67e-05	0.000119	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NRAS—skin cancer	2.25e-05	0.000101	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS2—skin cancer	2.14e-05	9.57e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KRAS—skin cancer	1.94e-05	8.66e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—skin cancer	1.72e-05	7.69e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HRAS—skin cancer	1.65e-05	7.36e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL6—skin cancer	1.58e-05	7.04e-05	CbGpPWpGaD
